background
thymu
transplant
promis
strategi
treatment
athym
complet
digeorg
syndrom
cdg
method
twelv
patient
cdg
underw
transplant
allogen
cultur
thymu
object
sought
confirm
extend
result
previous
obtain
singl
center
result
two
patient
die
preexist
viral
infect
without
thymopoiesi
late
death
occur
autoimmun
thrombocytopenia
one
infant
septic
shock
shortli
transplant
result
graft
loss
need
second
transplant
evid
thymopoiesi
develop
month
transplant
patient
median
circul
naiv
count
l
rang
l
l
rang
l
month
transplant
tcell
receptor
excis
circl
cell
rang
cell
cell
rang
digeorg
syndrom
dg
athymia
also
known
complet
digeorg
syndrom
cdg
result
state
profound
tcell
defici
causal
associ
review
elsewher
dg
associ
hemizyg
microdelet
chromosom
charg
coloboma
heart
defect
atresia
choana
retard
growth
develop
genit
abnorm
ear
abnormalitiesdeaf
syndrom
mutat
delet
chromosom
fetal
toxin
exposur
glucos
ethanol
retino
acid
around
children
delet
complet
form
dg
wherea
incid
problem
relat
caus
unknown
immunolog
phenotyp
either
profound
tcell
lymphopenia
patient
atyp
cdg
might
oligoclon
expans
memori
phenotyp
cell
confer
littl
protect
immun
caus
inflammatori
diseas
form
rash
enteropathi
lymphadenopathi
cdg
differ
sever
combin
immunodefici
scid
underli
defect
prevent
develop
thymu
wherea
underli
defect
scid
genet
defect
hematopoiet
lineag
patient
cdg
scid
similar
high
risk
earli
death
infect
two
approach
use
correct
immunodefici
patient
cdg
first
cellreplet
hematopoiet
stem
cell
transplant
hsct
absenc
thymu
approach
achiev
engraft
postthym
cell
although
number
report
longlast
surviv
patient
treat
way
particularli
match
sibl
donor
transplant
qualiti
immun
reconstitut
achiev
poor
surviv
match
unrel
donor
match
sibl
transplant
report
respect
altern
approach
use
thymu
transplant
aim
complet
reconstitut
abil
produc
naiv
cell
show
broad
tcell
receptor
tcr
repertoir
postnat
thymic
tissu
readili
avail
routin
remov
infant
undergo
open
heart
surgeri
median
sternotomi
approach
use
singl
center
unit
state
sinc
might
patient
select
bia
group
undergo
thymu
transplant
patient
sever
comorbid
seriou
opportunist
infect
exclud
nevertheless
result
compar
favor
outcom
hsct
approxim
longterm
surviv
patient
evid
thymopoiesi
divers
repertoir
naiv
circul
cell
capabl
hlarestrict
specif
antigen
respons
seen
survivor
nonsurviv
cohort
mostli
associ
pretransplant
morbid
mainli
viral
infect
chronic
lung
diseas
autoimmun
hypothyroid
rel
common
addit
number
patient
problem
transplant
seriou
potenti
lifethreaten
autoimmun
includ
immun
cytopenia
enteropathi
also
report
although
much
less
commonli
reason
occurr
complic
illunderstood
center
thymu
transplant
establish
london
provid
treatment
patient
europ
done
test
whether
technolog
could
success
translat
singl
center
make
treatment
approach
readili
avail
europ
report
outlin
result
first
patient
treat
month
followup
patient
recruit
qualifi
studi
typic
cdg
maximum
tcell
count
l
naiv
cell
absent
prolif
respons
pha
patient
atyp
cdg
less
naiv
cell
addit
least
follow
featur
congenit
heart
diseas
hypoparathyroid
hemizygos
delet
charg
syndrom
patient
detail
see
method
section
articl
onlin
repositori
wwwjacionlineorg
patient
typic
cdg
without
clonal
expans
given
immunosuppress
atyp
cdg
cyclosporin
use
transplant
control
inflammatori
diseas
continu
transplant
patient
also
treat
dose
mgkg
bodi
weight
rabbit
antithymocyt
globulin
atg
genzym
cambridg
mass
mgkg
methylprednisolon
administ
intraven
day
follow
mgkg
oral
prednisolon
day
detail
includ
screen
donor
transplant
procedur
describ
previous
see
method
section
articl
onlin
repositori
separ
thymus
cultur
specif
analysi
assess
cellular
composit
chang
period
cultur
detail
method
see
method
section
articl
onlin
repositori
flow
cytometr
analysi
mitogen
respons
measur
tcell
receptor
signal
joint
excis
circl
trec
level
involv
standard
test
possibl
donor
tcell
engraft
short
tandem
repeat
use
previous
describ
method
clonal
cell
assess
use
tcrvb
chain
spectratyp
popul
previous
describ
regulatori
treg
cell
number
measur
popul
use
intracellular
stain
forkhead
box
spectratyp
also
perform
treg
cell
popul
purifi
mean
cell
sort
base
hi
cell
compar
remain
cell
assess
treg
cell
function
total
cell
isol
cell
studi
cytotox
lymphocyteassoci
antigen
upregul
transendocytosi
base
previous
report
method
modifi
run
assay
period
rather
hour
fixingpermeabil
cell
allow
stain
total
rather
cycl
surfac
frequenc
ifngproduc
cell
respons
either
autolog
thirdparti
ebvtransform
lymphoblastoid
cell
line
lcl
specif
stimul
assess
pbmc
use
elispot
assay
previous
report
histolog
studi
perform
formalinfix
tissu
includ
immunohistochem
analysi
use
standard
method
describ
previous
detail
antibodi
use
given
method
section
articl
onlin
repositori
studi
approv
institut
child
health
great
ormond
street
hospit
research
ethic
committe
cover
thymu
donat
includ
screen
donor
transplant
procedur
recipi
thymic
cultur
undertaken
licens
uk
human
tissu
author
detail
patient
includ
genet
defect
comorbid
infect
acquir
transplant
shown
tabl
median
age
transplant
month
rang
month
case
molecular
basi
dg
undefin
although
one
case
put
mutat
found
analysi
perform
professor
klau
schwartz
univers
ulm
ulm
germani
neither
patient
infant
diabet
mother
atyp
cdg
case
outnumb
typic
case
ratio
evid
bcgassoci
diseas
recipi
vaccin
two
patient
hypothyroid
transplant
caus
establish
neg
test
result
thyroid
peroxisom
antibodi
one
low
thyroidstimul
hormon
valu
suggest
possibl
central
caus
wherea
problem
prove
transient
patient
clearcut
autoimmun
diseas
transplant
period
thymic
cultur
progress
lymphoid
cell
deplet
reciproc
increas
proport
epitheli
cell
adhes
molecul
epcam
posit
thymic
epitheli
cell
tec
fig
ac
small
fraction
cell
remain
predomin
singleposit
cell
fig
could
induc
activ
prolifer
fig
e
f
histolog
section
thymic
slice
surgic
procedur
well
toler
patient
wound
infect
problem
wound
heal
dose
thymu
transplant
rang
gm
bodi
surfac
area
patient
atyp
cdg
receiv
cyclosporin
receiv
atg
concern
potenti
worsen
preexist
viral
infect
one
patient
atyp
cdg
addit
receiv
cours
alemtuzumab
control
inflammatori
featur
within
month
transplant
nine
patient
aliv
median
followup
time
month
rang
month
two
patient
die
month
week
respect
transplant
preexist
viral
infect
dissemin
cytomegaloviru
cmv
parainfluenza
pneumon
respect
atg
withheld
one
patient
die
cerebr
hemorrhag
associ
immun
thrombocytopenia
month
transplant
first
thymic
graft
surviv
receiv
second
success
graft
month
clinic
detail
case
given
result
section
articl
onlin
repositori
wwwjacionlineorg
clinic
outcom
survivor
gener
good
except
mainli
autoimmun
problem
nonimmunolog
aspect
dg
tabl
ii
thymopoiesi
evidenc
detect
blood
naiv
cell
trec
without
addit
evid
biopsi
specimen
show
featur
thymopoiesi
skin
rash
three
patient
second
transplant
skin
rash
earli
week
transplant
underw
skin
biopsi
show
nonspecif
dermat
similar
spongiot
dermat
previous
describ
case
donor
dna
could
detect
skin
blood
patient
infect
clear
patient
abl
clear
rang
infecti
agent
transplant
includ
present
acquir
transplant
tabl
ii
j
allergi
clin
immunol
volum
number
case
receiv
bcg
vaccin
transplant
local
sever
inflammatori
respons
inocul
site
region
lymph
node
tcell
reconstitut
occur
primari
ebv
infect
occur
month
transplant
abl
clear
infect
although
lowlevel
ebv
viremia
persist
month
clear
receiv
chronic
immunosuppress
manag
clear
number
viral
infect
autoimmun
form
autoimmun
complic
occur
patient
surviv
month
tabl
ii
took
one
form
earli
onset
evid
tcell
immun
reconstitut
onset
tcell
reconstitut
detail
autoimmuneinflammatori
complic
patient
provid
result
section
articl
onlin
repositori
see
tabl
articl
onlin
repositori
wwwjacionlineorg
two
case
earlyonset
categori
hemolyt
anemia
respond
treatment
recur
patient
autoimmun
problem
occur
time
tcell
reconstitut
compris
mainli
cytopenia
thyroid
latter
associ
presenc
antithyroid
peroxisom
antibodi
number
transient
autoimmuneinflammatori
phenomena
also
occur
patient
soon
immun
reconstitut
possibl
identifi
associ
develop
autoimmun
methodolog
factor
includ
choic
thymu
donor
thymic
cultur
medium
use
amount
tissu
transplant
use
atg
condit
six
patient
surviv
month
partial
hla
match
loci
resolut
type
see
tabl
articl
onlin
repositori
wwwjacionlineorg
patient
without
autoimmun
complic
fell
boldfac
type
indic
infect
present
transplant
aiha
autoimmun
hemolyt
anemia
gh
growth
hormon
itp
immun
thrombocytopenia
rsv
respiratori
syncyti
viru
copiesml
blood
group
match
also
develop
autoimmun
although
one
transient
earli
hemolysi
patient
without
hla
match
experienc
autoimmun
one
transient
earli
hemolysi
trend
toward
less
autoimmun
presenc
hla
match
statist
signific
fisher
exact
test
immunolog
test
transplant
tcell
immun
donor
leukocyt
engraft
detect
patient
circul
tcell
number
surviv
patient
increas
around
month
naiv
cell
increas
around
month
transplant
fig
correl
naiv
cell
number
determin
use
differ
flow
cytometr
strategi
shown
fig
articl
onlin
repositori
wwwjacionlineorg
gener
cell
number
achiev
reach
normal
agerel
rang
see
tabl
articl
onlin
repositori
wwwjacionlineorg
continu
increas
naiv
cell
number
month
mainten
rel
steadi
level
low
number
cell
like
caus
immunosuppress
patient
receiv
longterm
immunosuppress
trec
show
similar
time
cours
naiv
cell
fig
rel
poor
correl
trec
naiv
cell
count
see
fig
normal
tcr
divers
demonstr
vb
spectratyp
cell
achiev
patient
includ
atyp
cdg
abnorm
spectratyp
abnorm
spectratyp
persist
patient
analysi
show
normal
spectratyp
wherea
spectratyp
abnorm
mitogen
respons
pha
fig
b
improv
patient
decreas
immunosuppress
unknown
reason
never
normal
patient
good
evid
thymopoiesi
biopsi
blood
analysi
primari
ebv
infect
pbmc
patient
show
abil
produc
good
ifng
respons
autolog
ebvtransform
lcl
respond
significantli
less
well
thirdparti
lcl
fig
c
phenotyp
circul
cell
marker
treg
cell
perform
patient
show
cell
present
low
absolut
number
although
express
proport
cell
differ
healthi
age
rangematch
control
group
fig
b
see
fig
articl
onlin
repositori
wwwjacionlineorg
proport
treg
cell
respect
wherea
control
subject
median
level
rang
function
abil
cell
patient
term
upregul
activ
transendocytosi
compar
adult
control
sampl
fig
c
correl
found
level
immunolog
reconstitut
achiev
factor
relat
choic
thymu
donor
thymic
cultur
medium
use
amount
tissu
transplant
use
atg
condit
bcell
immun
patient
receiv
immunoglobulin
replac
transplant
five
patient
stop
immunoglobulin
around
month
transplant
per
protocol
normal
igg
level
date
patient
immun
tetanu
toxoid
show
protect
respons
three
receiv
conjug
pneumococc
vaccin
made
good
protect
respons
one
patient
respond
vaccin
reimmun
iga
level
undetectableextrem
low
transplant
patient
low
gl
level
normal
transplant
survivor
except
bcell
number
remain
normal
see
fig
articl
onlin
repositori
wwwjacionlineorg
patient
except
receiv
treatment
mab
rituximab
proport
b
cell
igd
classswitch
memori
b
cell
test
patient
valu
remain
rel
low
compar
publish
agerel
control
subject
patient
wherea
other
within
normal
limit
particularli
year
see
fig
b
biopsi
transplant
thymic
slice
undertaken
patient
includ
transplant
median
time
month
rang
month
transplant
area
histolog
normal
thymic
tissu
seen
muscl
includ
corticomedullari
distinct
hassal
bodi
format
biopsi
specimen
biopsi
specimen
immunohistochem
stain
show
abund
cell
evid
cortic
thymopoiesi
defin
express
termin
deoxynucleotidyl
transferas
normal
matur
late
mtec
stage
defin
express
claudin
autoimmun
regul
air
involucrin
stain
show
presenc
frequent
posit
cell
fig
see
fig
articl
onlin
repositori
wwwjacionlineorg
biopsi
specimen
case
show
less
welldevelop
thymic
architectur
definit
evid
cortic
thymopoiesi
defin
presenc
cortic
thymocyt
data
shown
biopsi
specimen
evid
thymopoiesi
found
first
transplant
like
biopsi
specimen
miss
thymu
muscl
later
appear
thymic
emigr
blood
indic
thymopoiesi
die
cmv
biopsi
specimen
taken
month
show
viabl
thymic
epithelium
littl
thymopoiesi
see
fig
ad
articl
onlin
repositori
wwwjacionlin
org
cmv
could
demonstr
thymic
tissu
data
shown
die
earli
transplant
postmortem
examin
transplant
thymu
reveal
viabl
epithelium
extens
neovascular
see
fig
e
f
studi
show
transplant
cultur
thymic
epithelium
reconstitut
tcell
immun
patient
cdg
enabl
control
opportunist
infect
qualiti
life
restrict
suscept
infect
confirm
add
result
previous
report
seri
surviv
rate
level
immun
reconstitut
achiev
similar
seri
proport
children
autoimmun
complic
higher
present
studi
number
rel
small
difficult
know
whether
differ
signific
present
studi
novel
data
document
chang
cellular
composit
thymic
slice
cultur
provid
well
data
trec
level
achiev
number
phenotyp
function
treg
cell
also
detail
histolog
evid
thymic
biopsi
specimen
confirm
full
matur
mtec
although
patient
studi
recogn
genet
caus
fig
rel
total
fluoresc
intens
cell
acquir
green
fluoresc
protein
gfp
tag
onto
result
transendocytosi
shown
deriv
mean
fluoresc
intens
gfp
multipli
number
gfp
cell
get
total
fluoresc
intens
divid
number
treg
cell
acquir
panel
patient
control
subject
equival
result
p
j
allergi
clin
immunol
volum
number
dg
previou
studi
includ
number
case
includ
matern
diabet
show
patient
equival
outcom
level
tcell
reconstitut
achiev
surviv
patient
usual
normal
age
suffici
allow
clearanc
viral
infect
case
normal
mitogen
respons
achiev
divers
repertoir
demonstr
tcr
spectratyp
circul
treg
cell
could
detect
proport
similar
control
children
although
lower
absolut
number
function
shown
normal
apart
one
case
ifng
respons
ebv
shown
antigenspecif
tcell
respons
assay
studi
respons
studi
tetanu
candida
speci
antigen
previou
seri
show
posit
respons
surviv
patient
patient
followup
year
abl
stop
immunoglobulin
test
thu
far
normal
antibodi
respons
tetanu
normal
antibodi
respons
conjug
pneumococc
vaccin
iga
defici
correct
patient
number
classswitch
memori
b
cell
remain
rel
low
patient
assess
signific
find
longer
followup
need
determin
whether
proport
increas
time
reason
suboptim
number
cell
achiev
patient
clear
could
insuffici
thymic
tissu
transplant
fact
correl
studi
north
american
seri
amount
tissu
transplant
eventu
tcell
naiv
tcell
count
achiev
associ
count
type
medium
use
cultur
use
atg
presenc
chanc
overlap
hla
antigen
donor
recipi
shown
cultur
thymu
lose
lymphoid
cell
popul
cultur
rel
enrich
tec
howev
viabl
lymphoid
cell
capabl
prolifer
still
present
cell
might
necessari
mainten
growth
tec
theoret
cell
could
mediat
graftversushost
diseas
seen
blood
analysi
engraft
donor
hematopoiet
cell
detect
patient
one
situat
thymopoiesi
might
develop
context
preexist
cmv
infect
seen
studi
previou
studi
find
viabl
thymic
epithelium
thymopoiesi
biopsi
consist
possibl
viru
agent
use
treat
might
inhibit
develop
thymopoiesi
children
cdg
complic
cmv
infect
surviv
either
previou
studi
biopsi
transplant
thymu
shown
help
determin
whether
thymopoiesi
develop
report
biopsi
done
around
month
transplant
posit
result
show
evid
cortic
thymopoiesi
half
thymic
medulla
hassal
corpuscl
seen
present
studi
biopsi
done
later
median
month
posit
result
clear
corticomedullari
differenti
develop
hassal
corpuscl
immunohistochem
evid
differenti
mtec
proce
termin
stage
like
differ
time
biopsi
account
differ
previou
seri
present
previou
seri
autoimmun
complic
rel
common
predominantli
involv
thyroid
cytopenia
complic
transient
natur
might
reflect
immun
dysregul
tcell
reconstitut
sometim
seen
clinic
situat
hsctand
experiment
model
two
earli
case
autoimmun
seen
tcell
emerg
could
conceiv
noth
transplant
reason
suscept
autoimmun
complic
poorli
understood
possibl
inadequ
neg
select
nonmhcmatch
mtec
contribut
develop
autoimmun
support
find
previou
larger
studi
benefici
effect
chanc
partial
hla
match
conclus
studi
strengthen
case
thymu
transplant
correct
treatment
choic
cdg
offer
possibl
immun
reconstitut
degre
produc
qualiti
life
limit
infect
suscept
autoimmun
common
complic
often
manag
rel
easili
proport
children
experi
seriou
consequ
work
requir
understand
better
pathogenesi
problem
newborn
screen
program
scid
expand
patient
might
requir
treatment
work
need
streamlin
laborintens
process
requir
special
facil
gener
transplant
thymu
model
human
thymu
transplant
nude
mous
might
use
explor
patient
might
benefit
approach
includ
infant
scid
immun
reconstitut
hsct
gene
therapi
thymic
insuffici
follow
provid
technic
help
thymu
prepar
margaret
brocklesbi
geoffrey
white
chri
fisher
catherin
ingram
gulrukh
ahsan
patricia
plumbl
dr
john
hartley
jame
soothil
garth
dixon
provid
invalu
help
microbiolog
screen
donor
donor
thymus
dr
christin
rivat
help
sort
cell
spectratyp
patricia
cheng
nick
gedd
provid
invalu
help
manuscript
prepar
follow
assist
clinic
care
patient
tore
gunnar
abrahamsen
nathali
aladjidi
waseem
qasim
carolin
laffort
christin
vaksdal
nilsen
mariann
val
patient
refer
alreadi
artifici
ventil
sever
neurolog
defect
like
lifelimit
exclud
studi
patient
congenit
heart
diseas
requir
correct
cardiac
surgeri
thymu
transplant
delay
least
month
surgeri
cardiac
surgeri
delay
least
month
thymu
transplant
patient
continu
routin
antibiot
prophylaxi
cotrimoxazol
fluconazol
count
greater
l
normal
mitogen
respons
achiev
replac
dose
immunoglobulin
administ
minimum
year
thymu
transplant
addit
winter
month
patient
receiv
monthli
intramuscular
inject
palivizumab
prophylaxi
respiratori
syncyti
viru
thymu
gland
total
subtot
remov
time
cardiac
surgeri
median
sternotomi
infant
congenit
heart
diseas
collect
written
inform
consent
parent
thymu
donor
select
basi
abo
blood
group
compat
absenc
trisomi
known
chromosom
anomali
absenc
prior
known
infecti
risk
age
less
month
receipt
thymu
period
tissu
cultur
donor
infant
mother
screen
possibl
transmiss
diseas
includ
test
hepat
b
hepat
c
human
tlymphotrop
viru
toxoplasmosi
syphili
infant
mother
addit
test
carri
infant
cmv
urin
blood
thymu
tissu
ebv
adenoviru
blood
thymic
tissu
posit
result
test
result
thymu
discard
addit
donor
infant
screen
delet
use
either
fluoresc
situ
hybrid
array
compar
genom
hybrid
donor
mother
ask
complet
lifestyl
questionnair
give
risk
factor
transmiss
diseas
dna
extract
thymocyt
releas
slice
cultur
store
use
tissu
type
donor
thymu
prepar
cultur
describ
previous
briefli
capsul
thymu
remov
slice
stadierigg
microtom
thoma
scientif
swedesboro
nj
approxim
slice
mount
nitrocellulos
filter
millipor
temecula
calif
filter
place
spongostan
surgic
spong
ferrosan
medic
devic
soeborg
denmark
bath
cultur
medium
petri
dish
first
patient
medium
compris
serumfre
cellgro
invitrogen
carlsbad
calif
remain
patient
thymu
organ
medium
contain
fb
new
zealand
sourc
heat
inactiv
gamma
irradi
use
previous
describ
thymus
cultur
day
daili
chang
medium
regular
medium
cultur
taken
genusspecif
pcr
test
mycoplasma
speci
final
day
cultur
medium
subject
gram
stain
endotoxin
detect
assay
charl
river
wilmington
mass
weight
slice
estim
photograph
slice
measur
area
slice
imagej
program
avail
nation
institut
health
bethesda
md
assum
slice
mm
thick
densiti
gcm
histolog
assess
thymic
slice
undertaken
start
cultur
period
day
cultur
end
cultur
period
assess
thymic
epitheli
viabil
degre
lymphoid
deplet
decis
suitabl
transplant
taken
second
evalu
studi
cellular
composit
cultur
thymu
perform
separ
cultur
destin
transplant
singlecel
suspens
gener
thymic
slice
analyz
use
flow
cytometri
vari
time
point
tissu
weigh
digest
teas
cell
strainer
dulbecco
modifi
eagl
medium
sigma
st
loui
mo
remov
thymocyt
remaind
fine
disaggreg
scalpel
blade
tissu
fragment
enzymat
digest
minut
dulbecco
modifi
eagl
medium
mgml
dnase
roch
diagnost
mannheim
germani
mgml
collagenas
roch
diagnost
pass
cell
strainer
residu
materi
subject
second
round
enzymat
digest
also
includ
trypsin
sigma
edta
thymic
slice
older
day
requir
second
digest
step
gener
singlecel
suspens
digest
materi
pass
clean
cell
strainer
cell
wash
pb
fb
count
trypan
blue
prepar
flow
cytometri
tissu
digest
stain
fluorochromeconjug
antibodi
detect
thymocyt
nonhematopoiet
tec
thymocyt
retriev
cultur
slice
addit
subject
cellspecif
stimul
recombin
human
use
flow
cytometri
activ
prolifer
measur
assess
upregul
carboxyfluorescein
succinimidyl
ester
dilut
respect
reagent
ebiosci
san
diego
calif
thymu
transplant
describ
previous
briefli
slice
place
small
hole
quadricep
muscl
insolubl
stitch
use
pull
muscl
slice
base
previou
experi
duke
univers
estim
weight
thymic
tissu
transplant
cap
maximum
gm
recipi
bodi
surfac
area
patient
underw
regular
clinic
immunolog
assess
addit
regular
monitor
thyroid
function
monitor
presenc
antithyroid
peroxisom
antibodi
tcell
chimer
studi
undertaken
dna
extract
blood
sampl
skin
appear
rash
necessit
skin
biopsi
transplant
check
possibl
donor
tcell
engraft
use
short
tandem
repeat
previous
describ
method
biopsi
transplant
thymu
undertaken
case
involv
open
one
origin
surgic
wound
take
muscl
biopsi
specimen
area
previou
slice
insert
flow
cytometr
analysi
involv
label
whole
blood
combin
directli
conjug
mab
purchas
becton
dickinson
bioscienc
san
jose
calif
naiv
cell
assess
use
differ
flow
cytometr
strategi
normal
rang
lymphocyt
subset
naiv
popul
proport
class
switch
memori
b
cell
base
publish
data
mitogen
respons
assess
measur
tritiat
thymidin
incorpor
stimul
isol
mononuclear
cell
pha
concentr
mgml
normal
rang
pha
respons
base
analysi
consecut
inhous
healthi
adult
control
subject
assay
time
cours
studi
median
cpm
rang
cpm
thymic
output
also
assess
measur
trec
level
realtim
quantit
pcr
agerel
normal
rang
trec
level
base
inhous
unpublish
data
follow
antibodi
use
mous
antihuman
mous
antihuman
mous
antihuman
mous
antihuman
mous
antihuman
leica
biosystem
buffalo
grove
ill
mous
antihuman
ck
dako
glostrup
denmark
rat
antihuman
bd
bioscienc
san
jose
calif
rat
antihuman
ebiosci
rabbit
antihuman
claudin
zyme
laboratori
south
san
francisco
calif
mous
antihuman
air
kindli
provid
professor
p
peterson
univers
tartu
estonia
rabbit
covanc
princeton
nj
rat
development
studi
hybridoma
bank
univers
iowa
mous
antitermin
deoxynucleotidyl
transferas
dako
mous
antiinvolucrin
abcam
cambridg
unit
kingdom
failur
first
thymic
graft
surviv
evidenc
biopsi
specimen
show
viabl
thymu
evid
naiv
cell
circul
like
result
episod
sever
septic
shock
associ
streptococcu
faecali
central
venou
line
infect
occur
day
transplant
result
poor
tissu
perfus
patient
surviv
episod
abdomin
ebvneg
bcell
lymphoma
shown
host
cell
origin
month
transplant
success
treatment
chemotherapi
mab
treatment
second
transplant
procedur
undertaken
patient
patient
evid
anoth
intraabdomin
bcell
lymphoprolif
process
month
second
transplant
resolv
treatment
rituximab
recur
year
followup
comparison
result
use
flow
cytometr
strategi
detect
naiv
cell
show
excel
correl
cell
although
analys
result
correl
less
well
result
method
fig
fig
b
ad
hematoxylin
eosin
stain
respect
patient
show
nest
thymic
epithelium
present
muscl
lymphoid
cell
suggest
littl
thymopoiesi
e
f
hematoxylin
eosin
stain
respect
strand
thymic
tissu
muscl
patient
show
extens
neovascular
week
transplant
